Filter Results:
- Full text PDF available (3)
Publication Year
2010
2017
- This year (1)
- Last 5 years (4)
- Last 10 years (5)
Publication Type
Co-author
Journals and Conferences
Learn More
- Godefridus J. Peters, Kees Smid, +11 authors Deog Joong Kim
- Investigational New Drugs
- 2013
A novel cytidine analog fluorocyclopentenylcytosine (RX-3117; TV-1360) was characterized for its cytotoxicity in a 59-cell line panel and further characterized for cytotoxicity, metabolism and… (More)
- Fuhong Su, Hongchuan Huang, +6 authors J. R. Vincent
- Shock
- 2010
We compared the effects of a new compound (TV7130) with those of activated protein C (APC) in a large animal model of septic shock. Thirty-two fasted, anesthetized, invasively monitored, mechanically… (More)
- Joel F. Kaye, Victor Piryatinsky, +16 authors Ralph Laufer
- Proceedings of the National Academy of Sciences…
- 2016
Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington's disease. Laquinimod exerts beneficial… (More)
- Michal Geva, Rebecca L Kusko, +15 authors Michael R. Hayden
- Human molecular genetics
- 2016
Pridopidine has demonstrated improvement in Huntington Disease (HD) motor symptoms as measured by secondary endpoints in clinical trials. Originally described as a dopamine stabilizer, this mechanism… (More)
- Marta Garcia-Miralles, Michal Geva, +9 authors Mahmoud A Pouladi
- JCI insight
- 2017
Pridopidine is currently under clinical development for Huntington disease (HD), with on-going studies to better characterize its therapeutic benefit and mode of action. Pridopidine was administered… (More)
- ‹
- 1
- ›